01—Abstract
Summary
Summary of the 8-K filed May 6, 2026. Cited figures are marked; the original filing is the authoritative source.
Revolution Medicines, Inc. (Nasdaq: RVMD) reported financial results for the quarter ended March 31, 2026, and provided a corporate update.
The most prominent development is positive topline results from the Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer, where the intent-to-treat population showed a median overall survival of 13.2 months versus 6.7 months for chemotherapy (hazard ratio 0.40; p<0.0001). The company intends to submit these data to global regulators, including a New Drug Application to the FDA under the Commissioner's National Priority Voucher program, and to present them at an ASCO Plenary Session. Financially, net loss widened to $453.8 milliona for the quarter from $213.4 million a year earlier, driven by higher research and development expenses of $344.0 million (versus $205.7 million) and general and administrative expenses of $101.3 million (versus $35.0 million).
Stock-based compensation rose to $87.3 millionb, including an incremental $44.6 million tied to a new retirement-benefit provision in the equity program. The company raised $2.2 billion in gross proceeds from April 2026 concurrent offerings, and cash, cash equivalents and marketable securities were $1.9 billion as of March 31, 2026.
Full-year 2026 GAAP operating expenses guidance was updated to $1.7 to $1.8 billionc, and full-year stock-based compensation is now expected to be $260 to $280 million. The filing also outlines pipeline milestones for 2026, including RASolve 301 enrollment, the RASolve 308 trial start in zoldonrasib first-line NSCLC, an elironrasib registrational strategy update, RM-055 first-in-human trial initiation in the fourth quarter, and expansion of commercial leadership in Japan, Asia Pacific and Europe.
02—Key points
Key Highlights
- RASolute 302 Phase 3 trial: daraxonrasib achieved median overall survival of 13.2 months vs. 6.7 months for chemotherapy in previously treated metastatic pancreatic cancer (hazard ratio 0.40; p<0.0001), with results considered final for PFS and OS.
- Regulatory path: the company plans to submit RASolute 302 data to global authorities, including an FDA New Drug Application under the Commissioner's National Priority Voucher program, and to present at an ASCO Plenary Session.
- Net loss of $453.8 million for Q1 2026, up from $213.4 million in Q1 2025, driven by R&D expense of $344.0 million and G&A expense of $101.3 million.
- Stock-based compensation of $87.3 million in Q1 2026 included an incremental $44.6 million from a new retirement-benefit provision; full-year 2026 stock-based compensation guidance is $260 to $280 million.
- Full-year 2026 GAAP operating expenses guidance updated to $1.7 to $1.8 billion.
- Balance sheet: $2.2 billion in gross proceeds from April 2026 concurrent offerings ($1,725.0 million common stock and $500.0 million 0.50% convertible senior notes due 2033); cash, equivalents and marketable securities were $1.9 billion at March 31, 2026, with stockholders' equity of $1.50 billion.
- 2026 milestones: RASolve 308 start in first half, RASolve 309 start in second half, RMC-5127 Phase 2 dose identification in second half, and RM-055 first-in-human trial initiation in Q4 2026.
03—Questions
Frequently Asked Questions
What were the key clinical results from the RASolute 302 trial?
In the overall intent-to-treat population of the Phase 3 RASolute 302 trial in second-line metastatic pancreatic cancer, daraxonrasib demonstrated a median overall survival of 13.2 months versus 6.7 months for chemotherapy (hazard ratio 0.40; p<0.0001). The company reported statistically significant and clinically meaningful improvements in progression-free survival and overall survival, with no new safety signals.
What regulatory steps does the company plan next for daraxonrasib?
Revolution Medicines intends to submit the RASolute 302 data to global regulatory authorities, including as part of a New Drug Application to the FDA under the Commissioner's National Priority Voucher program. The results will also be presented in a Plenary Session at the 2026 ASCO Annual Meeting. An Expanded Access Program for previously treated PDAC has also been initiated.
Why did operating expenses and net loss increase in the first quarter of 2026?
R&D expenses rose to $344.0 million from $205.7 million, primarily due to higher clinical trial and manufacturing costs for daraxonrasib and zoldonrasib, personnel costs from added headcount, and higher stock-based compensation. G&A expenses rose to $101.3 million from $35.0 million, reflecting stock-based compensation, headcount, commercial preparation activities and administrative costs. Net loss was $453.8 million compared with $213.4 million a year earlier.
How did the company change its stock-based compensation expectations?
In Q1 2026 the company updated its equity compensation program to introduce retirement benefits for employees meeting specific age and service requirements. This accelerated recognition of expense for eligible awards, including an incremental $44.6 million in the quarter. Full-year 2026 stock-based compensation expense is now expected to be between $260 and $280 million, an increase of approximately $80 million, which drove the updated full-year GAAP operating expenses guidance of $1.7 to $1.8 billion.
How strong is the company's liquidity position?
Cash, cash equivalents and marketable securities were $1.9 billion as of March 31, 2026, down from $2.03 billion at December 31, 2025. In April 2026 the company received $2.1 billion in net proceeds from concurrent financings totaling $2.2 billion in gross proceeds. Working capital was $1.68 billion and total stockholders' equity was $1.50 billion at March 31, 2026.
04—Continue